Survival in women with MMR mutations and ovarian cancer: A multicentre study in Lynch syndrome kindreds

Journal of Medical Genetics

Volumn 47, Issue 2, 2010, Pages 99-102

  Grindedal, Eli Marie ^a   Renkonen Sinisalo, Laura ^b   Vasen, Hans ^c   Evans, Gareth ^d   Sala, Paola ^e   Blanco, Ignacio ^f   Gronwald, Jacek ^g   Apold, Jaran ^h   Eccles, Diana M ⁱ   Sánchez, Ángel Alonso ^j   Sampson, Julian ^k   Järvinen, Heikki J ^b   Bertario, Lucio ^e   Crawford, Gillian C ⁱ   Stormorken, Astrid Tenden ^a   Maehle, Lovise ^a   Moller, Pal ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

^e NATIONAL CANCER INSTITUTE   (Italy)

^f Translational Research Laboratory   (Spain)

^g POMERANIAN MEDICAL UNIVERSITY   (Poland)

^h HAUKELAND UNIVERSITY HOSPITAL   (Norway)

ⁱ UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^j Universidad Pública de Navarra   (Spain)

^k CARDIFF UNIVERSITY   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; FAMILIAL CANCER; FEMALE; GENE; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MLH1 GENE; MMR GENE; MSH2 GENE; MSH6 GENE; MULTICENTER STUDY; ONCOGENE; OVARY CANCER; PRIORITY JOURNAL; SALPINGOOOPHORECTOMY;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; DNA MISMATCH REPAIR; DNA-BINDING PROTEINS; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; MIDDLE AGED; MUTATION; MUTS HOMOLOG 2 PROTEIN; NUCLEAR PROTEINS; OVARIAN NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 77349086189     PISSN: 00222593     EISSN: 14686244     Source Type: Journal    
DOI: 10.1136/jmg.2009.068130     Document Type: Article

References (15)

1. Aarnio M, Sankila R, Pukkala E, Salovaara R, Aaltonen LA, de la Chapelle A, Peltomäki P, Mecklin JP, Järvinen HJ. Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer 1999;81:214-18.
2. Watson P, Vasen HF, Mecklin JP, Bernstein I, Aarnio M, Järvinen HJ, Myrhøj T, Sunde L, Wijnen JT, Lynch HT. The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome. Int J Cancer 2008;123:444-9.
3. Boilesen AE, Bisgaard ML, Bernstein I. Risk of gynecologic cancers in Danish hereditary non-polyposis colorectal cancer families. Acta Obstet Gynecol Scand 2008;87:1129-35.
4. Watson P, Bützow R, Lynch HT, Mecklin JP, Järvinen HJ, Vasen HF, Madlensky L, Fidalgo P, Bernstein I. International Collaborative Group on HNPCC. The clinical features of ovarian cancer in hereditary nonpolyposis colorectal cancer. Gynecol Oncol 2001;82:223-8.
5. Crijnen TE, Janssen-Heijnen ML, Gelderblom H, Morreau J, Nooij MA, Kenter GG, Vasen HF. Survival of patients with ovarian cancer due to a mismatch repair defect. Fam Cancer 2005;4:301-5.
6. Lu KH. Hereditary gynecologic cancers: differential diagnosis, surveillance, management and surgical prophylaxis. Fam Cancer 2008;7:53-8.
7. Bertagnolli MM. Surgical prevention of cancer. J Clin Oncol 2005;23:324-32.
8. Schmeler KM, Lu KH. Gynecologic cancers associated with Lynch syndrome/HNPCC. Clin Transl Oncol 2008;10:313-17.
9. Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Kwan E, Jack E, Vesprini DJ, Kuperstein G, Abrahamson JL, Fan I, Wong B, Narod SA. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 2001;68:700-10.
10. Heimdal K, Maehle L, Apold J, Pedersen JC, Møller P. The Norwegian founder mutations in BRCA1: high penetrance confirmed in an incident cancer series and differences observed in the risk of ovarian cancer. Eur J Cancer 2003;39:2205-13.
11. Evans GR, Gaarenstroom KN, Stirling D, Shenton A, Maehle L, Dørum A, Steel M, Lalloo F, Apold J, Porteous M, Vasen HF, van Asperen C, Moller P. Screening for familial ovarian cancer: poor survival of BRCA1/2 related cancers. J Med Genet 2008;15. doi:10.1136/jmg.2008.058248.
12. Cancer Registry of Norway. Long-term cancer survival: patterns and trends in Norway 1965-2007. In: Cancer in Norway 2007. Cancer incidence, mortality, survival and prevalence in Norway Oslo, 2008:17.
13. Rosenthal AN, Menon U, Jacobs IJ. Screening for ovarian cancer. Clin Obstet Gynecol 2006;49:433-47.
14. Maehle L, Apold J, Paulsen T, Hagen B, Løvslett K, Fiane B, Van Ghelue M, Clark N, Møller P. High risk for ovarian cancer in a prospective series is restricted to BRCA1/2 mutation carriers. Clin Cancer Res 2008;14:7569-73.
15. Hogg R, Friedlander M. Biology of epithelial ovarian cancer: implications for screening women at high genetic risk. J Clin Oncol 2004;22:1315-27.